Belzupacap sarotalocan is a recombinant protein commercialized by Aura Biosciences, with a leading Phase II program in Uveal Melanoma. According to Globaldata, it is involved in 6 clinical trials, of which 1 was completed, 3 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Belzupacap sarotalocan’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Belzupacap sarotalocan is expected to reach an annual total of $28 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Belzupacap sarotalocan Overview

AU-011 is under development for the treatment of ocular melanoma (melanomas of the iris and the ciliary body), uveal and choroidal melanoma. It is administered as an intravitreal, suprachoroidal, intratumoral and intramural route. The therapeutic candidate is developed based on Nanosmart technology. The drug candidate is a VDC (virus like drug conjugate).

Aura Biosciences Overview

Aura Biosciences is working on a novel class of oncology targeted therapeutics that will provide considerable therapeutic benefit to a variety of cancer indications with a high unmet need. The company is headquartered in United States.

The operating loss of the company was US$35.3 million in FY2021, compared to an operating loss of US$22.2 million in FY2020. The net loss of the company was US$35.3 million in FY2021, compared to a net loss of US$22.2 million in FY2020.

For a complete picture of Belzupacap sarotalocan’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.